InsidersTradesSigma
Follow the 上海莱士 share price and the full directors' dealings record of the company, a listed equity based in China. Shares trade on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 上海莱士 has logged 6 public disclosures. Market capitalisation: €32.3bn. The latest transaction was reported on 21 April 2026 (Purchase). Among the most active insiders: JUN XU. All data is accessible without an account.
6
Insider Decl.
n/a
Thresholds
€1m
6 ops.
Buy Volume
n/a
n/a
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,604 of 29,063 companies
50.0
score / 100
Value42
Quality58
FCF yld-2.2%
Earn yld4.8%
EV/EBITDA16.8x
ROE4.1%
Gross mgn37%
Net mgn21%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 April 2026
Declarations6 total
6 of 6 declarations
关于 上海莱士
上海莱士是一家健康和制药领域的公司，在 XSHE 市场上市。该公司专注于创新医药产品的开发和生产。